InBioMed: (Institute of Biochemical Medicine) is a Research, Education and Community Service institution. RECNAC-II Project, (which spells CANCER backwards), is InBioMed´s main research project, and its primary goal is the development of a non-toxic protocol to treat cancer and reverse its adverse effects. The Educational Branch has a part within the academic structure of the University of Puerto Rico, and external educational programs for Continuing Education for Professionals as well as for the General Public. The Service Branch includes corporative and clinical consultation.
Doctors González and Miranda-Massari, founders of InBioMed, are leaders in the development of non-toxic chemotherapy treatments for cancer. The findings of their work with Intravenous Vitamin C as an anti-cancer agent, published in 2002, were confirmed by the NIH in 2005. They published the first Phase-I clinical study utilizing Intravenous Vitamin C for treatment of terminal cancer patients in 2005, and also published in 2005 the most comprehensive review on Vitamin C and Cancer, as a follow-up on the work of two times Nobel Laureate, Dr. Linus C. Pauling.